Abstract Objective: Small cell prostate carcinoma (SCPC) is a rare and highly malignant subtype of prostate cancer. SCPC frequently lacks androgen receptor (AR) and prostate-specific antigen (PSA) expression, and often responds poorly to androgen deprivation therapy (ADT). AR splice variant-7 (AR-V7) is a truncated AR protein implicated in resistance to AR-targeting therapies. AR-V7 expression in castration-resistant prostate cancers has been evaluated extensively, and blood-based detection of AR-V7 has been associated with lack of response to abiraterone and enzalutamide. However, whether AR-V7 is expressed in SCPC is not known. Methods: Using validated antibodies, we performed immunohistochemistry (IHC) assay for the full-length AR (AR-FL) and (AR-V7) on post-ADT surgical SCPC specimens. Results: Seventy-five percent (9/12) of the specimens showed positive staining for the AR-FL with various intensities. Thirty-three percent (4/12) of the specimens showed positive staining for AR-V7. Among the specimens with positive AR-V7 staining, two samples displayed very weak staining, one sample showed weak-to-moderate staining, and one sample showed strong staining. All positive specimens displayed a heterogeneous pattern of AR-FL/AR-V7 staining. All specimens positive for AR-V7 were also positive for AR-FL. 
Introduction
Small cell prostate carcinoma (SCPC) is a rare and highly malignant subtype of prostate cancer. SCPC only accounts for 0.5%e2% of untreated primary prostate cancer at initial diagnosis [1, 2] , but can present in up to 25% metastatic castration-resistant prostate cancer (CRPC) autopsies [3] . SCPC frequently lacks expression of androgen receptor (AR) and AR downstream target genes such as prostate-specific antigen (PSA), and often responds poorly to androgen deprivation therapy (ADT) [2] . The widespread application of potent next-generation hormonal therapies such as enzalutamide and abiraterone may also lead to increased occurrences of treatment related SCPC [4] .
Resistance to ADT in prostate cancer is often associated with aberrant androgen receptor (AR) activities mediated by AR protein overexpression, AR gene amplification, mutation and emergence of constitutively active AR variants such as AR splice variant-7 (AR-V7) [5e7]. However, detailed expression pattern of different AR isoforms in primary SCPC patients who received prior ADT remains poorly characterized. In this study, we have developed and validated antibodies for immunohistochemistry (IHC) assays suitable for evaluation of full length AR (AR-FL) and AR-V7 in primary SCPC specimens. The expression of AR-FL and AR-V7 protein were determined in post-ADT radical prostatectomy (RP) or transurethral resection of the prostate (TURP) samples from 12 SCPC patients.
Materials and methods

Patients and tissue samples
This research was approved by the Institutional Review Board (IU IRB 1808872882). SCPC specimens were collected surgically via RP or TURP. All the patients were previously treated with hormonal therapy. The patients' age ranged from 43 to 87 years old (mean, 70 years). Eleven cases were from TURP and one from RP (SC-06).
IHC assays
For AR C-terminus IHC, the antigen retrieval was done by placing the de-paraffinized slides in Antigen Unmasking Solution, Tris-Based High pH (H-3301; Vector Lab, Burlingame, CA, USA) at 95 C for 40 min. The slides were incubated with the rabbit monoclonal anti-human AR Cterminus antibody (1:200; Sigma-Aldrich, Saint Louis, MO, USA, catalog number: SAB5500007) for 1 h at room temperature. The secondary antibody was a ready-to-use antirabbit poly HRP IgG (PowerVision, PV6118; Leica Biosystems, Buffalo Grove, IL, USA) and was incubated with the slides for 30 min at room temperature.
For AR-V7 IHC, the antigen retrieval was done by placing the de-paraffinized slides in Antigen Unmasking Solution, Tris-Based High pH (H-3301) at 95 C for 20 min. The slides were incubated with the rabbit monoclonal anti-human AR-V7 antibody (1:200, RevMAb Biosciences, South San Francisco, CA, USA, catalog number: 31-1109-00) for 70 min at room temperature. The secondary antibody was a ready-to-use anti-rabbit poly HRP IgG (PowerVision, PV6118) and it was incubated with the slides for 30 min at room temperature.
All the stained slides were scanned by Leica Biosystems Aperio AT2 Digital Pathology scanner (Leica Biosystems Imaging, Buffalo Grove, IL, USA) at 40Â magnification. The IHC staining nuclear RGB intensity value was determined by Aperio ImageScope (Leica Biosystems Imaging, Buffalo Grove, IL, USA) using algorithm developed by Johns Hopkins University. The nuclear AR-FL staining intensity was classified as negative (nuclear RGB intensity value 220e250) and positive (nuclear RGB intensity value 219). The AR-FL positive nuclear staining was further classified as weak (nuclear RGB intensity value 200e219), moderate (nuclear RGB intensity value 180e199) and strong (nuclear RGB intensity 155e179). The nuclear AR-V7 staining intensity was classified as negative (nuclear RGB intensity value 220e250) and positive (nuclear RGB intensity value 219). Positive AR-V7 nuclear staining was further classified as weak (nuclear RGB intensity value 210e220), moderate (nuclear RGB intensity value 188e209) and strong (nuclear RGB intensity value 162e187). The total number of cells were determined by hematoxylin staining using Aperio ImageScope (Leica Biosystems Imaging, Vista, CA, USA). The percentage of positive tumor cells was calculated as number of cells with positive AR-FL or AR-V7 nuclear staining divided by total number of cells in the tissue. Samples were defined as AR-FL or AR-V7 positive if the total number of AR-FL or AR-V7 positive tumor cells were above 0.5% in the tissue.
Results
Validation of AR-FL and AR-V7 IHC assays
The antibodies targeting AR-FL and AR-V7 were validated using prostate cancer cell lines with known AR profiles. Both antibodies were tested in LNCaP95 cells, which express both AR-FL and AR-V7, and the AR-negative PC3 cells [8] . The Western blot for the AR-V7 antibody (RevMab, South San Francisco, CA, USA) was examined and demonstrated in a previous publication from our group [9] . The Western blot for the AR-C-terminal domain (AR-CTD) antibody (Sigma, Saint Louis, MO, USA) only showed a single specific band for AR-FL as shown in Fig. 1 , along with the IHC results. In LNCaP95 cells, both AR-V7 and AR-FL were detected predominantly in the nuclei, consistent with the expected expression pattern in this cell line. The antibodies showed good specificity to the corresponding antigens given lack of IHC staining in the AR-negative PC3 cell line.
AR-FL and AR-V7 protein expression in post-ADT SCPC cases
Twelve surgical (RP or TURP) SCPC specimens were collected from patients after neoadjuvant hormonal therapy at Indiana University School of Medicine. The diagnosis of SCPC was based on 2016 WHO classification system [10] . Seventy-five percent (9/12) of the specimens showed positive AR-FL nuclear staining with varying intensities. Thirty-three percent (4/12) of the specimens showed positive nuclear staining for AR-V7. The summary of the staining results is shown in Table 1 . The quantification of the staining was achieved by using Aperio ImageScope (Leica Biosystems Imaging, Vista, CA, USA) and the algorithm was developed by Johns Hopkins University.
Among the four specimens with positive AR-V7 staining, two samples (SC-03 and SC-04) displayed very weak staining, one sample (SC-02) showed weak-to-moderate staining, and one sample (SC-01) showed strong staining. All positive specimens displayed a heterogeneous pattern of AR/AR-V7 staining. All specimens positive for AR-V7 were also positive for the AR-FL. Sample staining results of AR-V7 and AR-CTD are shown in Fig. 2. 
Discussion
SCPC is one of the most lethal forms of prostate cancer. It has usually metastasized at initial diagnosis, and would not respond to hormonal therapy. Cisplatin or doxorubicinbased chemotherapies are the main treatment, and the median overall survival of SCPC is significantly shorter compared to usual adenocarcinoma. In general, SCPC does not express prostate cancer specific markers such as AR and PSA. However, recent studies suggested SCPC may also express detectable level of AR and AR targeted genes [11] . In a recent xenograft study, a fraction of AR-positive enzalutamide-resistant tumors carried neuroendocrine features, indicating an AR-indifferent status [12] . This finding indicate that SCPC, especially those that arise after treatments, may continue to express AR-FL and AR-V7. AR-FL is detected in a substantial proportion of SCPC specimens. It is currently unknown why detection of AR-FL do not confer response to AR-targeting therapies (e.g., enzalutamide or abiraterone) in SCPC patients. It is possible that although some SCPC cells remains AR-FL positive, they may become "AR-indifferent" [13] .
Our study is limited by the small sample size (n Z 12). However, the purpose of the study was to evaluate AR- FL/AR-V7 protein expression in SCPC specimens. We used an AR-V7 antibody that had been extensively validated in a recent study using CRPC specimens [9] . The current study generated a few notable observations. First, this is the first study establishing AR-V7 protein can be detected in SCPC specimens using a validated antibody. Second, the heterogeneous pattern of AR-FL/AR-V7 expression indicates that AR-FL/AR-V7 positive cells may coexist with AR negative cells in SCPC, possibly reflecting a transition state from an AR-driven disease to ARindifferent or AR-independent disease. Third, consistent with results from non-SCPC CRPC specimens, we did not observe cells that were AR-V7 positive but AR-FL negative, further supporting the conclusion that AR-V7 always coexists with AR-FL [14] . 
Conclusion
The study demonstrated AR-FL/AR-V7 expression in a substantial fraction of treatment related SCPC specimens. The functional and clinical relevance of AR/AR-V7 detection in this setting remains unknown. This finding, however, may help to interpret liquid biopsy-based detection of AR-V7 in patients with low PSA. Future investigation will focus on clinical correlation in an expanded patient cohort. 
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